April 24, 2024

• 

[THE INVESTOR] As of Jan. 17 11:10 A.M., Mezzion Pharma declined 2.59% from yesterday to 20,650 won (US$17.42). It fell 5.28% over the past month. Standard deviation for the one month period stood at 2.6%.

Compared with its industry competitors listed on KOSDAQ, the investment return for the one month was at a low level, and its volatility for the one month was around the average of its peer group.

The monthly return-on-risk, indicating the return on investment with consideration for risk, was -2.0%. Compared with the rest of the KOSPI industry, the return-on-risk was lower than the industrial mean of 0.9%.

■ Earnings & Valuation

Mezzion Pharma (140410)

Earnings report for 3Q (July – Sept.) of 2016
Revenue: 13.1 T   Down 45.4% on-quarter, down 11.2% on-year
Operating income: -15.7 T   
Net income: -47.3 T   

Investor Groups (Over the past five trading days)
Institutions 4.33%, Foreigners 7.00%, Individuals 88.65%

*Other investor groups including corporations are considered as “individuals.”

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.